Description

With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice.

The book first reviews fundamental issues including epidemiology, screening, risk reduction, diagnosis and pathologic characterization, staging, and imaging. This includes strategies for improving the accuracy of PSA screening and an update on controversies surrounding the ISUP Modified Gleason Score. The book covers novel molecular and genotype profiling in prostate cancer, including morphometric and systems pathology. Detailed information is provided on radiographic imaging for diagnosis and staging. The treatment sections of the book correspond to the staging of disease. The treatment of localized disease addresses the range of multidisciplinary management options including a discussion of prostate cancer's impact on the quality of life. A detailed review of multimodal therapies (medical, surgical, and radiologic) addresses the treatment of localized advanced disease, and coverage of advanced metastatic prostate cancer reviews current management options including a range of promising novel and experimental agents. The book also discusses counseling the high-risk patient. Several chapters incorporate models of care delivery, patient navigation for multidisciplinary care, genomic and risk assessment, and comparative effects of research in treatment decision-making. The book is designed as a management text for all health care professionals who provide care for prostate cancer patients as well as patients, families, and advocates. Extensive references offer opportunities for additional study.
Key Features:

· Delineates a practical, concise approach to multidisciplinary management of prostate cancer

· Provides a wide range of perspectives and expertise

· Written and edited by an international, multidisciplinary team of prostate cancer specialists

· Focuses on such key issues as special populations, screening controversies, patient counseling, and quality of life

· Includes discussion of important emerging topics such as gene profiling and targeted therapies and comparative effectiveness data



Table of Contents

Contributors

Series Foreword

Preface

Acknowledgments

I. Epidemiology, Screening, and Diagnosis

1 Introduction: The Multidisciplinary Approach to Prostate Cancer Leonard G. Gomella

2.1 Epidemiology of Prostate Cancer Kathryn M. Wilson, Lorelei A. Mucci

2.2 Diet and Prostate Cancer James R. Marshall

2.3 Epidemiology: Obesity as a Risk Factor. Emma H. Allott, Stephen J. Freedland

3.1.1 Screening and Diagnosis: The Pros of PSA Screening, Janine L. Oliver, Gurdarshan S. Sandhu, Gerald L. Andriole, Robert L. Grubb III

3.1.2 The Argument Against Prostate Cancer Screening, Otis W. Brawley

3.1.3 How Do We Improve PSA Accuracy?, Toru Sugihara, Michael W. Kattan

3.2 Screening and Diagnosis: An Update on the ISUP-Modified Gleason Score and Its Controversies, Ibrahim Kulac, Angelo M. DeMarzo

3.3 Evaluation of Distant Disease: The Utility of Nuclear Imaging, Dima Raskolnikov, Baris Turkbey, Liza Lindenberg, Peter L. Choyke, Peter A. Pinto

4 Current Approaches to Prostate Cancer Staging and Risk Stratification: In the Midst of a Paradigm Shift, Chad A. Reichard, Eric A. Klein

5.1 Novel Molecular and Genotype Profiling in Prostate Cancer: The Future of Screening, Diagnosis, and Staging, Heesun Shin, Ismael A. Vergara, Anirban P. Mitra

5.2 Genomics and Risk Assessment, Hao G. Nguyen, Matthew R. Cooperberg, Peter R. Carroll

5.3 Future Direction: Novel Urine and Serum Markers, Waleed A. Hassen

5.4 Morphometric and Systems Pathology: The Future of Screening, Diagnosis, and Staging, Michael J. Donovan, Faisal M. Kha, Richard Scott, Gerardo Fernandez, Carlos Cordon-Cardo

5.5.1 PET: The Future of Screening, Diagnosis, and Staging for Prostate Cancer,Mathew L. Thakur, Edouard J. Trabulsi, Sung M. Kim, Charles M. Intenzo, Leonard G. Gomella

5.5.2 DCE MRI and MR Spectroscopy: The Future of Screening, Diagnosis, and Staging,Victor Sai, Antonio C. Westphalen

5.5.3 Future Direction: Contrast Ultrasound 109, Sanjay Kasturi, Edouard J. Trabulsi, Ethan J. Halpern

6 Counseling Patients With Clinically Localized, High-Risk Prostate Cancer, Jonathan L. Silberstein, James A. Eastham



II. Treatment for Low-Risk, Localized Disease

7 Active Surveillance for Prostate Cancer: An Overview, Laurence Klotz

8 Treatment of Low-Risk, Localized Prostate Cancer: A Holistic Approach With Diet, Jillian Scambia, Annie Darves-Bornoz, Aaron Katz

9.1 Traditional Radical Prostatectomy, Zachary L. Smith, Thomas J. Guzzo

9.2 Laparoscopic Radical Prostatectomy: Techniques and Complications, Fernando Pablo Secin, Karim Touijer

9.3 Robotic Radical Prostatectomy: The Thomas Jefferson University Experience, Costas D. Lallas, Edouard J. Trabulsi

9.4 Surgical Training, Digital Capture, Virtual Reality, and the Future of Radical Prostatectomy, Costas D. Lallas

10.1.1 External Beam Radiation Therapy: Conventional Fractionation, David E. Greene, Richard K. Valicenti

10.1.2 Hypofractionated Radiation Therapy for Localized Prostate Cancer, Nicholas G. Zaorsky, Robert B. Den

10.1.3 Stereotactic Body Radiation Therapy for Localized Prostate Cancer, Nicholas G. Zaorsky, Robert B. Den

10.1.4 Treatment of Low-Risk, Localized Prostate Cancer: Use of Proton Therapy, Phillip J. Gray, Ayal A. Aizer, Jason A. Efstathiou

10.2 Treatment of Low-Risk, Localized Prostate Cancer: Brachytherapy, Peter Grimm

11.1 Treatment of Low-Risk, Localized Prostate Cancer: General Principles of Ablative and Focal Therapies, Joshua A. Cohn, , Aytekin Oto, Scott E. Eggener

11.2 Hyperthermia for Prostate Cancer, Mark Hurwitz

11.3 Ablative Techniques: Vascular Targeted Photodynamic Therapy, Ashley G. Winter, Jonathan A. Coleman

11.4 Laser Ablative Techniques for Prostate Cancer, Ashley G. Winter, Jonathan A. Coleman

11.5 Irreversible Electroporation (IRE) Prostate Ablation, Ashley G. Winter, Jonathan A. Coleman

12.1 Quality of Life With Surgery, Alana M. Murphy, Patrick J. Shenot

12.2 Quality of Life With Androgen Deprivation Therapy, Alana M. Murphy, Patrick J. Shenot

12.3 Quality of Life With External Beam Radiation Therapy, Steve K. Williams, Sameer Chopra, Farhang Rabbani

12.4 Quality of Life With Brachytherapy for Low-Risk Localized Prostate Cancer, Steve K. Williams, Farhang Rabbani

13 Role for Comparative Effectiveness Research in Treatment Decision Making, Ryan T. Jones, Mark V. Mishra, Timothy N. Showalter

14 Defining Treatment Failure for Localized Prostate Cancer: PSA and Beyond, Nicholas G. Zaorsky, Robert B. Den, Jianqing Lin

15 Prognosis After Biochemical Failure and Surrogate Endpoints for Prostate Cancer-Specific Mortality, Peter Orio, Nathan Bittner

III. Treatment for High-Risk, Localized, and Locally Advanced Disease

16 Treatment of High-Risk Prostate Cancer: The Role of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy, Thomas J. Pugh

IV. Treatment of Disseminated Disease

17 Salvage Therapy for Rising PS, Judd W. Moul

18 Metastatic Hormone Sensitive Prostate Cancer, Jean Hoffman-Censits, William Kevin Kelly

19.1 Metastatic Castrate-Resistant Prostate Cancer: Mechanisms of Hormone Escape, Susan F. Slovin

19.2 Metastatic Castrate-Resistant Prostate Cancer: Role of Chemotherapy and Multifaceted Treatment Paradigms, Abdel Hai Alqwasmi, Nicholas G. Zaorsky, Ulka Vaishampayan

19.3 Metastatic Castrate-Resistant Prostate Cancer: Role of Androgen Signaling Inhibitors, Austin Poole, Ajjai Alva, Julia Batten, Neeraj Agarwal

19.4.1 Radiation and the Immune System, Andrew Sharabi, Charles Drake

19.4.2 Immunotherapy: Agents Targeting Prostate Cancer, Gurveen Kaur, Naveed H. Akhtar, Beerinder K. Singh, Scott T. Tagawa

19.5 Treatment of Bony Metastases: Inhibitors of Bone Resorption, Clara Hwang, Elisabeth I. Heath

19.6 Treatment of Bone Metastases: Radiopharmaceuticals, Hossein Jadvar, Leslie Ballas, David I. Quinn

19.7 Prognostication of Metastatic Castration-Resistant Prostate Cancer, Alan D. Smith, Joaquin Mateo, Johann S. de Bono

Index
This title is available for license in the following territories:

This title is can be found in the following categories: